This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|June 9, 2020
Siemens and Exyte Collaborate to Provide Modular Biopharma Facilities
Author(s)BioPharm International Editors
Siemens and Exyte partner for fast-track construction of modular, automated, digitalized biopharmaceutical facilities.
Advertisement
Siemens and Exyte are collaborating to offer end-to-end solutions for the biopharmaceutical industry by combining Siemens’ digitalization expertise with Exyte’s engineering design and the company’s modular technology for rapid construction of biopharmaceutical facilities, the companies announced in a June 9, 2020 press release. The standardized, turnkey solutions are compliant with current good manufacturing practice and good automated manufacturing practice. Currently, the first buildings with Siemens’ technology and ExyCell modules are being designed for cell and gene therapy manufacturing and biologicals production in China and Europe.
Siemens says its process automation platforms will be embedded in the prefabricated, modular facilities. Siemens also offers power supply and fire protection for modular cleanrooms.
“Our collaboration allows our clients to reap the benefits of industry 4.0 without the necessity of engineering them from scratch each time,” said Luca Mussati, vice-president of pharmaceuticals and biotechnology at Exyte, in the June 9, 2020 press release. He noted that the modules are suitable for new buildings as well as for the retrofit of existing buildings, and are available in standard, off-the-shelf plant configurations, or customized modules.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5